Bioavailability and Short-Term Tolerability of Alendronate in Glucocorticoid-Treated Children

Clinical Therapeutics

Volumn 33, Issue 10, 2011, Pages 1516-1523

  Nakhla, Meranda ^a   Denker, Andrew E ^b   Connor, James D ^c   Carpenter, Thomas O ^d   Walson, Philip D ^e   Porras, Arturo G ^b   Matthews, Catherine Z ^b   Larson, Patrick ^b   Freeman, Amanda ^b   Wagner, John A ^b   Ward, Leanne M ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d YALE UNIVERSITY   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Alendronate; Bioavailability; Bisphosphonates; Children; Glucocorticoids; Tolerability

Indexed keywords

ALENDRONIC ACID; GLUCOCORTICOID;

ABDOMINAL PAIN; ADOLESCENT; ANKLE EDEMA; ARTICLE; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSMENORRHEA; FACE PAIN; FEMALE; FLUID RETENTION; HEARTBURN; HUMAN; HYPERTENSION; INSOMNIA; KNEE PAIN; LEG PAIN; LEG SWELLING; LIMB PAIN; MALE; NECK PAIN; OTALGIA; OUTCOME ASSESSMENT; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; URINARY EXCRETION; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ALENDRONATE; BIOLOGICAL AVAILABILITY; BONE DENSITY CONSERVATION AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAVENOUS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 80054956111     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.001     Document Type: Article

References (37)

1. van Staa T.P., Cooper C., Leufkens H.G., Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003, 18:913-918.
2. Ward L.M., Denker A.E., Porras A., et al. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab 2005, 90:4051-4056.
3. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995, 333:1437-1443. The Alendronate Phase III Osteoporosis Treatment Study Group.
4. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998, 339:292-299. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
5. Golden N.H., Iglesias E.A., Jacobson M.S., et al. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005, 90:3179-3185.
6. Bianchi M.L., Cimaz R., Bardare M., et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000, 43:1960-1966.
7. Rudge S., Hailwood S., Horne A., et al. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford) 2005, 44:813-818.
8. Schwartz G.J., Brion L.P., Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987, 34:571-590.
9. Kline W.F., Matuszewski B.K. Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivatization and high-performance liquid chromatography with fluorescence and electrochemical detection. J Chromatogr 1992, 583:183-193.
10. Therapeutic Products Directorate Guidelines: ICH Harmonised Tripartite Guideline: General Considerations for Clinical Trials 1997, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Health Canada, Ottawa, Canada.
11. Gertz B.J., Holland S.D., Kline W.F., et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995, 58:288-298.
12. Porras A.G., Holland S.D., Gertz B.J. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999, 36:315-328.
13. Kunzmann V., Bauer E., Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 1999, 340:737-738.
14. DiMeglio L.A., Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 2006, 21:132-140.
15. Inoue Y., Shimojo N., Suzuki S., et al. Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. Clin Rheumatol 2008, 27:909-912.
16. Dicuonzo G., Vincenzi B., Santini D., et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 2003, 23:649-654.
17. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005, 353:1711-1723.
18. Unal E., Abaci A., Bober E., Buyukgebiz A. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. J Pediatr Endocrinol Metab 2006, 19:523-528.
19. Lethaby C., Wiernikowski J., Sala A., et al. Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience. J Pediatr Hematol Oncol 2007, 29:613-616.
20. Hawker G.A., Ridout R., Harris V.A., et al. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy. Arch Phys Med Rehabil 2005, 86:284-288.
21. El-Husseini A.A., El-Agroudy A.E., El-Sayed M.F., et al. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant 2004, 8:357-361.
22. Falcini F., Trapani S., Ermini M., Brandi M.L. Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcif Tissue Int 1996, 58:166-169.
23. Cho T.J., Choi I.H., Chung C.Y., et al. Efficacy of oral alendronate in children with osteogenesis imperfecta. J Pediatr Orthop 2005, 25:607-612.
24. Millonig G., Graziadei I.W., Eichler D., et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 2005, 11:960-966.
25. Seikaly M.G., Kopanati S., Salhab N., et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 2005, 25:786-791.
26. Sholas M.G., Tann B., Gaebler-Spira D. Oral bisphosphonates to treat disuse osteopenia in children with disabilities: a case series. J Pediatr Orthop 2005, 25:326-331.
27. Akcay T., Turan S., Guran T., Bereket A. Alendronate treatment in children with osteogenesis imperfecta. Indian Pediatr 2008, 45:105-109.
28. Apkon S., Coll J. Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy. Am J Phys Med Rehabil 2008, 87:139-143.
29. Borzutzky A., Reyes M.L., Figueroa V., et al. Osteoporosis in children with severe congenital neutropenia: bone mineral density and treatment with bisphosphonates. J Pediatr Hematol Oncol 2006, 28:205-209.
30. Freundlich M., Alon U.S. Bisphosphonates in children with hypercalciuria and reduced bone mineral density. Pediatr Nephrol 2008, 23:2215-2220.
31. Khadilkar V.V., Khadilkar A.V., Maskati G.B. Oral bisphosphonates in polyostotic fibrous dysplasia. Indian Pediatr 2003, 40:894-896.
32. Lteif A.N., Zimmerman D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics 1998, 102(4 Pt 1):990-993.
33. Maasalu K., Haviko T., Martson A. Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatr 2003, 92:452-455.
34. Madenci E., Yilmaz K., Yilmaz M., Coskun Y. Alendronate treatment in osteogenesis imperfecta. J Clin Rheumatol 2006, 12:53-56.
35. Mukamel M., Horev G., Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 2001, 138:763-766.
36. Pizones J., Plotkin H., Parra-Garcia J.I., et al. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. J Pediatr Orthop 2005, 25:332-335.
37. Vyskocil V., Pikner R., Kutilek S. Effect of alendronate therapy in children with osteogenesis imperfecta. Joint Bone Spine 2005, 72:416-423.